Adocia (ADOC.PA) Action Cours
Adocia Cours
Le chiffre d'affaires a progressé de 53,6 % par an au cours des 17 dernières années pour atteindre 1,48 M EUR. La marge nette de Adocia s'établit à -1 124,8 %, en hausse par rapport aux -1 575,8 % d'il y a quelques années.
Cours de l'action Adocia
Action Adocia et analyse boursière
Questions fréquemment posées sur l'action Adocia
9 analystes notent actuellement l’action Adocia : 8 recommandent l’achat, 1 la conservation et 0 la vente.
L’action Adocia (ADOC.PA) est cotée sur 6 places boursières, notamment : London (0QAI.L), Frankfurt (A89.F), München (A89.MU), Düsseldorf (A89.DU), Paris (ADOC.PA).
Adocia SA is a French biotech company that focuses on the development of innovative insulin therapies and other biopharmaceutical preparations. The business model of Adocia is based on the research and development of novel therapy approaches that have a wide range of applications and high efficacy. Adocia operates in three main business areas: diabetes, autoimmune diseases, and cancer. In the diabetes field, the company is working on insulin preparations that help patients with type 1 and type 2 diabetes better control their blood sugar levels. The company has developed a range of insulin products, including an ultra-rapid insulin formulation, a long-acting combination formulation, and a combination formulation with glucagon-like peptide-1 (GLP-1). Adocia is also working on the development of therapies for autoimmune diseases such as Crohn's disease and multiple sclerosis. An innovative product from Adocia is a drug combination based on antibodies against tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). This drug combination has the potential to reduce inflammation in a range of autoimmune diseases. Another important business area of Adocia is cancer therapy. Adocia focuses on the development of drug combinations based on antibodies and other biological therapies. These drug combinations have the potential to attack cancer cells in various ways while stimulating the body's immune system. To finance the development of these therapies, Adocia has developed an innovative financing model. The company works closely with investment banks and venture capital funds to raise funds needed for the research and development of new therapy options. Adocia is also involved in successful public offerings and has the opportunity to explore further financing options through the issuance of shares. Adocia has successfully entered into partnerships with other companies in the industry to jointly develop innovative therapies. The company has also entered into a number of license agreements to utilize the intellectual property of other companies and enhance its own processes and technologies. Overall, Adocia's business model is focused on the research and development of novel therapies for diabetes, autoimmune diseases, and cancer. The company has an impressive product pipeline and a strong financial base that enables it to continue its innovative research efforts. Adocia is a pioneer in the biopharmaceutical industry and is expected to continue to play a key role in improving the health of millions of patients worldwide.
Le chiffre d'affaires ne peut pas être calculé pour Adocia pour le moment.
Le bénéfice de attendu en Adocia est de -12,14 M EUR. Le bénéfice net reflète la rentabilité de l'entreprise après déduction de tous les frais.
Le ratio cours/bénéfice (P/E) de Adocia est actuellement de -3,36. Le ratio P/E compare le cours actuel de l'action au bénéfice par action et aide les investisseurs à évaluer la valorisation de l'action Adocia.
Le ratio P/S ne peut pas être calculé pour Adocia pour le moment.
Le score de qualité Eulerpool pour Adocia est de 1/10.
L'ISIN de Adocia est FR0011184241. L'ISIN (International Securities Identification Number) est un identifiant global unique pour les titres.
Le WKN de Adocia est A1JTC2. Le WKN (Wertpapierkennnummer) est un numéro allemand d'identification des titres à six chiffres.
Le symbole boursier de Adocia est ADOC.PA. Ce code boursier est utilisé pour négocier les actions Adocia à la bourse.
Action Adocia
Groupe de pairs Adocia
Adocia Ticker
Adocia FIGI
Tous les fondamentaux et analyses approfondies de Adocia
Notre analyse de l'action Adocia comprend des indicateurs financiers importants tels que le chiffre d'affaires, le bénéfice, le P/E ratio, le P/S ratio, l'EBIT ainsi que des informations sur le dividende. De plus, nous examinons des aspects tels que les actions, la capitalisation boursière, les dettes, les fonds propres et les obligations de Adocia. Si vous recherchez des informations plus détaillées sur ces sujets, nous proposons des analyses approfondies sur nos sous-pages: